MARI.VI
Price:
$19.7
Market Cap:
$35.03M
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name t...[Read more]
Industry
Biotechnology
IPO Date
2019-02-01
Stock Exchange
VIE
Ticker
MARI.VI
According to Marinomed Biotech AG’s latest financial reports and current stock price. The company's current ROE is -103.28%. This represents a change of -784.49% compared to the average of 15.09% of the last 4 quarters.
The mean historical ROE of Marinomed Biotech AG over the last ten years is -264.34%. The current -103.28% ROE has changed -60.93% with respect to the historical average. Over the past ten years (40 quarters), MARI.VI's ROE was at its highest in in the September 2021 quarter at 332.34%. The ROE was at its lowest in in the June 2021 quarter at -186.89%.
Average
-264.34%
Median
62.98%
Minimum
-3078.00%
Maximum
153.90%
Discovering the peaks and valleys of Marinomed Biotech AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.64%
Maximum Annual ROE = 153.90%
Minimum Annual Increase = -189.31%
Minimum Annual ROE = -3078.00%
| Year | ROE | Change |
|---|---|---|
| 2024 | 58.93% | -12.08% |
| 2023 | 67.03% | -56.44% |
| 2022 | 153.90% | -105.00% |
| 2021 | -3078.00% | 2.64% |
| 2020 | -112.18% | 68.91% |
| 2019 | -66.41% | -189.31% |
| 2018 | 74.36% | 57.19% |
| 2017 | 47.31% | -36.55% |
| 2016 | 74.56% | -45.62% |
The current ROE of Marinomed Biotech AG (MARI.VI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
93.29%
5-year avg
-582.06%
10-year avg
-264.34%
Marinomed Biotech AG’s ROE is
| Company | ROE | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marinomed Biotech AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Marinomed Biotech AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Marinomed Biotech AG's ROE?
How is the ROE calculated for Marinomed Biotech AG (MARI.VI)?
What is the highest ROE for Marinomed Biotech AG (MARI.VI)?
What is the 3-year average ROE for Marinomed Biotech AG (MARI.VI)?
What is the 5-year average ROE for Marinomed Biotech AG (MARI.VI)?
How does the current ROE for Marinomed Biotech AG (MARI.VI) compare to its historical average?